A5106382057- Salivary Gland Disorders and Functions
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- Salivary Gland Tumors Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Autoimmune and Inflammatory Disorders Research
- Cancer Immunotherapy and Biomarkers
- Biosimilars and Bioanalytical Methods
- Inflammatory Myopathies and Dermatomyositis
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Diabetes and associated disorders
- SARS-CoV-2 and COVID-19 Research
- Galectins and Cancer Biology
- Inflammatory Bowel Disease
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Immunodeficiency and Autoimmune Disorders
- Growth Hormone and Insulin-like Growth Factors
- Chemokine receptors and signaling
- Eosinophilic Disorders and Syndromes
- COVID-19 Clinical Research Studies
- Spondyloarthritis Studies and Treatments
- Gout, Hyperuricemia, Uric Acid
Hôpitaux Universitaires de Strasbourg
2016-2025
Université de Strasbourg
2014-2025
Hôpital d'Hautepierre
2012-2024
Immunologie, Immunopathologie et Chimie Thérapeutique
2016-2024
Institut de Biologie Moléculaire et Cellulaire
2016-2024
Centre National de la Recherche Scientifique
2016-2024
Oklahoma Medical Research Foundation
2022
Center for Rheumatology
2022
University of Birmingham
2021
Sandwell & West Birmingham Hospitals NHS Trust
2021
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
<h3>Objectives</h3> To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing most recent developments in field. <h3>Methods</h3> An international task force was formed and solicited three systematic literature research activities on safety efficacy disease-modifying antirheumatic drugs (DMARDs) glucocorticoids (GCs). The new evidence discussed light last from 2019. A predefined voting process applied to each overarching principle recommendation....
<h3>Background</h3> Biological disease-modifying anti-rheumatic drugs (bioDMARDs) are generally used in combination with conventional synthetic DMARDs (csDMARDs) the treatment of rheumatoid arthritis (RA). Anti-TNF agents more effective csDMARDs (COMBO) than as monotherapy (MONO), while this is debated some newer bioDMARDs.(1) In particular, no difference was found patients (pts) insufficient response to TNF-inhibitors taking abatacept (ABA) MONO vs. COMBO.(2) <h3>Objectives</h3> To compare...
Patients with active rheumatoid arthritis (RA) despite treatment biologic disease-modifying antirheumatic drug (bDMARD) therapy need options.To evaluate the effects of filgotinib vs placebo on signs and symptoms RA in a treatment-refractory population.A 24-week, randomized, placebo-controlled, multinational phase 3 trial conducted from July 2016 to June 2018 at 114 sites internationally, randomizing 449 adult patients (and treating 448) moderately severely inadequate response/intolerance 1...
Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence these lack guidance for rheumatologists addressing them, a European League Against Rheumatism task force was convened to harmonise expert opinion regarding their identification management.First, group formulated research questions systematic literature review. Then, based on using consensus procedure, 4...
Importance Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in active Objective To compare the efficacy of tocilizumab vs placebo Design, Setting, and Participants This double-blind, parallel-group, placebo-controlled randomized clinical trial enrolled 101 rheumatica at 17 hospitals France from February 2017 to October 2019. Final follow-up occurred November 2020. Inclusion criteria were persistent...
BackgroundSjögren's disease is a heterogenous autoimmune with wide range of symptoms—including dryness, fatigue, and pain—in addition to systemic manifestations an increased risk lymphoma. We aimed identify distinct subgroups the disease, using cluster analysis based on subjective symptoms clinical biological manifestations, compare prognoses patients in these subgroups.MethodsThis study included Sjögren's from two independent cohorts France: cross-sectional Paris-Saclay cohort prospective...
Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice patients inflammatory arthritis (IA) and history cancer. To perform systematic literature review to inform Task Force formulating EULAR points consider on the initiation targeted IA Specific research questions were defined within before exact queries librarian. We included studies reporting relative measure cancer initiating therapy or conventional synthetic...
To investigate the role of rheumatoid factor (RF) status and anti-citrullinated peptide antibody (ACPA) as predictors abatacept (ABA) effectiveness in patients with arthritis (RA).We conducted a pooled analysis data from 9 observational RA registries Europe (ARTIS [Sweden], ATTRA [Czech Republic], BIOBADASER [Spain], DANBIO [Denmark], GISEA [Italy], NOR-DMARD [Norway], ORA [France], Reuma.pt [Portugal], SCQM-RA [Switzerland]). Inclusion criteria were diagnosis RA, initiation ABA treatment,...
Abstract Objective To compare the effectiveness and safety of three non-tumour necrosis factor (TNF) α inhibitors (rituximab, abatacept, tocilizumab) in treatment rheumatoid arthritis. Design Population based prospective study. Setting 53 university 54 non-university clinical centres France. Participants 3162 adults (>18 years) with arthritis according to 1987 American College Rheumatology criteria, enrolled one French Society registries; who had no severe cardiovascular disease, active...
Heterogeneity is a major obstacle to developing effective treatments for patients with primary Sjögren's syndrome. We aimed develop robust method stratification, exploiting heterogeneity in patient-reported symptoms, and relate these differences pathobiology therapeutic response.
Objectives To evaluate efficacy and safety of abatacept in adults with active primary Sjögren’s syndrome (pSS) a phase III, randomised, double-blind, placebo-controlled trial. Methods Eligible patients (moderate-to-severe pSS [2016 ACR/European League Against Rheumatism (EULAR) criteria], EULAR Syndrome Disease Activity Index [ESSDAI] ≥5, anti-SS-related antigen A/anti-Ro antibody positive) received weekly subcutaneous 125 mg or placebo for 169 days followed by an open-label extension to day...
Objectives No immunomodulatory drug has been approved for primary Sjögren’s syndrome, a systemic autoimmune disease affecting 0.1% of the population. To demonstrate efficacy targeting interleukin 6 receptor in patients with syndrome-related complications. Methods Multicentre double-blind randomised placebo-controlled trial between 24 July 2013 and 16 2018, follow-up 44 weeks, involving 17 referral centres. Inclusion criteria were syndrome according to American European Consensus Group score...
To characterise safety of the Janus kinase-1 preferential inhibitor filgotinib in patients with moderately to severely active rheumatoid arthritis.Data were integrated from seven trials (NCT01668641, NCT01894516, NCT02889796, NCT02873936, NCT02886728, NCT02065700, NCT03025308). Results are placebo (PBO)-controlled (through week (W)12) and long-term, as-treated (all available data for receiving ≥1 dose 200 (FIL200) or 100 mg (FIL100) daily) datasets. We calculated exposure-adjusted incidence...
The aim of this study was to characterize the safety and efficacy filgotinib, lanraplenib tirabrutinib in patients with active SS.
<h3>Objective</h3> To identify a specific pattern of serum cytokines that correlates with the diagnosis, activity and severity rheumatoid arthritis (RA) in patients early RA as well level markers B cell activation. <h3>Methods</h3> Serum interleukin (IL)-1β, IL-1 receptor antagonist (IL1-Ra), IL-2, IL-4, IL-6, IL-10, IL-17, IL-21, monocyte chemotactic protein 1 (MCP-1), tumour necrosis factor α interferon γ levels were measured (ESPOIR) Etude et Suivi des POlyarthrites Indifférenciées...
RF and ACPA are used as diagnostic tools their presence has been associated with clinical response to some biologic DMARDs (bDMARDs) in RA. This study compared the impact of seropositivity on drug discontinuation effectiveness bDMARDs patients RA, using head-to-head comparisons a real-world setting.We conducted pooled analysis 16 observational RA registries. Inclusion criteria were diagnosis initiation treatment rituximab (RTX), abatacept (ABA), tocilizumab (TCZ) or TNF inhibitors (TNFis)...
Abstract Objective HCQ is frequently used to treat primary SS (pSS), but evidence for its efficacy limited. blocks IFN activation, which present in half of the pSS patients. The effect treatment on expression IFN-stimulated genes (ISGs) was studied pSS. Furthermore, HCQ-treated patients were stratified based activation and differences disease activity clinical parameters studied. Methods Expression ISGs scores determined 77 patients, who previously enrolled placebo-controlled JOQUER trial....
Beyond its effect on vegetative functions, the activation of vagus nerve inhibits inflammation and reduces pain signaling. The aim this open-label pilot study was to determine efficacy tolerance transcutaneous auricular VNS (taVNS) erosive hand osteoarthritis (EHOA) symptoms. Symptomatic EHOA patients with VAS ≥ 40/100 mm ≥1 interphalangeal swollen joint(s) were included. taVNS performed for 4 weeks using an electrode applied one hour per day connected a TENS device pre-established settings....
Objectives Alterations in tryptophan (Trp) metabolism have been reported inflammatory diseases, including rheumatoid arthritis (RA). However, understanding whether these alterations participate RA development and can be considered putative therapeutic targets remains undetermined. In this study, we combined quantitative Trp metabolomics the serum from patients with corrective administration of a recombinant enzyme experimental to address question. Methods Targeted was performed on 574...
To update the long-term safety profile of filgotinib, a Janus kinase-1 preferential inhibitor, in patients with moderate-to-severe rheumatoid arthritis.
Interleukin-6 (IL-6) is a key cytokine in rheumatoid arthritis pathogenesis. We aimed to analyze the association between IL-6 serum levels and joint inflammation at baseline correlation of time-integrated values with structural damage during first 36 months early arthritis.IL-6 was assessed by 2 different methods 813 patients French cohort ESPOIR (Etude et Suivi des Polyarthrites Indifférenciées Récentes) over months. C-reactive protein (CRP) changes were correlated radiographic progression...